Latka logo
Nuvation Bio logo

Nuvation Biorevenue & market cap

New YorkFounded 2018CEO David Hung

Public company

Nuvation Bio is a global oncology company focused on tackling some of the toughest challenges in cancer treatment.

nuvationbio.comLinkedInUpdated Sep 28, 2026
Annual revenue
$62.9M
Dec 2025 · Stock Analysis+699% YoY
Market cap
$2B
Sep 2026

Nuvation Bio revenue

Nuvation Bio's annual revenue was $62.9M in December 2025 (Stock Analysis). That is up 699% from $7.9M a year earlier.

$0
$20M
$40M
$60M
$0
–
$7.9M
$62.9M
20182019–2320242025
ReportedFounded 2018 at $0; every reading has its own bar
All 2 revenue readings, with sources
As ofRevenueSource
Dec 2024$7.9MStock Analysis
Dec 2025$62.9MStock Analysis

Nuvation Bio market cap

Nuvation Bio is a public company. Its market capitalisation was $2B in September 2026.

Nuvation Bio CEO

David Hung is CEO of Nuvation Bio.

Nuvation Bio FAQ

What is Nuvation Bio's revenue?

Nuvation Bio's annual revenue was $62.9M in December 2025, according to Stock Analysis.

Is Nuvation Bio publicly traded?

Yes. Nuvation Bio is a public company, with a market capitalisation of $2B in September 2026.

Who is the CEO of Nuvation Bio?

David Hung is the CEO of Nuvation Bio.

Categories

How this page is sourced

2 from public sources. Founder figures link to the second they were said; public figures name their source; estimates are marked EST and say whose they are. Not financial advice.

Updated Sep 28, 2026Data disclaimerReport a correctionClaim this profileRun Nuvation Bio? Join the podcast